Teva intros generic Taxotere

NORTH WALES, Pa. — Teva Pharmaceuticals recently announced that it had launched its generic Taxotere (docetaxel) injection concentrate, for intravenous infusion. The drug is indicated to treat certain types of breast cancer, non-small cell lung cancer, hormone refractory prostate cancer and gastric adenocarcinoma. 

 

“Our customers count on Teva for a continuous supply of new generic products,” Maureen Cavanaugh, Teva SVP and general manager of U.S. generics said. “With the launch of docetaxel injection ... we add another quality product to our broad line of affordable generic pharmaceuticals.”